Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus

• Published in: Clinical microbiology and infection Vol. 27; no. 6; pp. 910.e1 - 910.e8
• Main Authors: Werth, Brian J., Ashford, Nathaniel K., Penewit, Kelsi, Waalkes, Adam, Holmes, Elizabeth A., Ross, Dylan H., Shen, Tianwei, Hines, Kelly M., Salipante, Stephen J., Xu, Libin
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2021
• Subjects: Cross-resistance; Daptomycin; Lipoglycopeptide; MRSA; PK/PD; Seesaw effect; VISA; walK; walR; β-lactam; Lipoglycopeptide; PK/PD; Cross-resistance; Daptomycin; MRSA; walR; VISA; Seesaw effect; β-lactam; walK

Dalbavancin is a lipoglycopeptide active against methicillin-resistant Staphylococcus aureus (MRSA). Its long half-life (8.5–16 days) allows for once-weekly or single-dose treatments but could prolong the mutant selection window, promoting resistance and cross-resistance to related antimicrobials su...